

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	<b>OSPREY MEDICAL INC.</b>
<b>ABN</b>	<b>ARBN 152 854 923</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Sandra Lesenfants
<b>Date of last notice</b>	9 April 2021

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct	
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	N/A	
<b>Date of change</b>	14 May 2021	
<b>No. of securities held after change</b>	211,833	Options (OSPAO) with exercise price of A\$0.38 per Share
	40,000	Options (OSPAO) with exercise price of A\$0.26 per Share
	331,713	Options (OSPAO) with exercise price of A\$0.05 per Share
	434,366	Options (OSPAO) with exercise price of A\$0.05 per Share
	Total: <u>1,017,912</u> Options (OSPAO) (exercisable into an equivalent of 2,035,824 CDIs)	

+ See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

<b>Class issued</b>	Options over Shares (not quoted)	
<b>No. of securities issued</b>	500,000 Options (OSPAO) (exercisable into an equivalent of 1,000,000 CDIs)	
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	Nil consideration. Issue of Options to Sandra Lesenfants was in accordance with the Osprey Medical 2016 Stock Incentive Plan.	
<b>Number disposed/cancelled</b>	Nil	
<b>No. of securities held after change</b>	211,833	Options (OSPAO) with exercise price of A\$0.38 per Share
	40,000	Options (OSPAO) with exercise price of A\$0.26 per Share
	331,713	Options (OSPAO) with exercise price of A\$0.05 per Share
	434,366	Options (OSPAO) with exercise price of A\$0.05 per Share
	500,000	Options (OSPAO) with exercise price of A\$0.034 per Share
	Total: <u>1,517,912</u> Options (OSPAO) (exercisable into an equivalent of 3,035,824 CDIs)	
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Grant of Options pursuant to stockholder approval granted at the Annual Meeting of Stockholders held on 11 May 2021. The exercise price of the Options upon vesting is \$0.34.	

## Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
<b>Interest after change</b>	N/A

**Part 3 – +Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?</b>	N/A
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

---

+ See chapter 19 for defined terms.